Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger
NCT ID: NCT03044756
Last Updated: 2017-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2017-01-01
2017-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antagonist Protocol in IVF
NCT02335736
Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles
NCT04008966
Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
NCT01093443
Trigger Timing in Ovarian Stimulations
NCT04163133
Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist
NCT01347268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
-ve arm
The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
Omit Citrotide 0.25 dose on the day of triggering of ovulation
Omit Citrotide 0.25 dose on the day of triggering of ovulation
+ve arm
The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omit Citrotide 0.25 dose on the day of triggering of ovulation
Omit Citrotide 0.25 dose on the day of triggering of ovulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Osama Saber Thabet Abdalmageed
Lecturer of OBGYN, Women Health Hospital, Assiut Univerisity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Osama Abdalmageed
Asyut, Non-US/Non-Canadian, Egypt
Osama Abdalmageed
Asyut, Non-US/Non-Canadian, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chang HJ, Lee JR, Jee BC, Suh CS, Lee WD, Kim SH. Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study. Clin Exp Reprod Med. 2013 Jun;40(2):83-9. doi: 10.5653/cerm.2013.40.2.83. Epub 2013 Jun 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Omit
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.